Longeveron/$LGVN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Longeveron
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
Ticker
$LGVN
Sector
Primary listing
Employees
38
Headquarters
Website
Longeveron Metrics
BasicAdvanced
$25m
-
-$1.29
-0.19
-
Price and volume
Market cap
$25m
Beta
-0.19
52-week high
$1.80
52-week low
$0.48
Average daily volume
773k
Financial strength
Current ratio
1.334
Quick ratio
1.166
Long term debt to equity
2.978
Total debt to equity
14.52
Profitability
EBITDA (TTM)
-22.061
Gross margin (TTM)
66.97%
Net profit margin (TTM)
-1,893.58%
Operating margin (TTM)
-1,942.20%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-81.27%
Return on equity (TTM)
-164.75%
Valuation
Price to revenue (TTM)
12.475
Price to book
3.44
Price to tangible book (TTM)
5.76
Price to free cash flow (TTM)
-0.777
Free cash flow yield (TTM)
-128.63%
Free cash flow per share (TTM)
-1.095
Growth
Revenue change (TTM)
-49.87%
Earnings per share change (TTM)
-50.63%
3-year revenue growth (CAGR)
-0.63%
3-year earnings per share growth (CAGR)
-47.61%
What the Analysts think about Longeveron
Majority rating from 2 analysts.
Longeveron News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Longeveron stock?
Longeveron (LGVN) has a market cap of $25M as of May 04, 2026.
What is the P/E ratio for Longeveron stock?
The price to earnings (P/E) ratio for Longeveron (LGVN) stock is 0 as of May 04, 2026.
Does Longeveron stock pay dividends?
No, Longeveron (LGVN) stock does not pay dividends to its shareholders as of May 04, 2026.
When is the next Longeveron dividend payment date?
Longeveron (LGVN) stock does not pay dividends to its shareholders.
What is the beta indicator for Longeveron?
Longeveron (LGVN) has a beta rating of -0.19. This means that it has an inverse relation to market volatility.